Indian Journal of Nuclear Medicine
Home | About IJNM | Search | Current Issue | Past Issues | Instructions | Ahead of Print | Online submissionLogin 
Indian Journal of Nuclear Medicine
  Editorial Board | Subscribe | Advertise | Contact
Users Online: 698 Print this page  Email this page Small font size Default font size Increase font size


 
 Table of Contents     
INTERESTING IMAGE
Year : 2020  |  Volume : 35  |  Issue : 4  |  Page : 367-369  

Dynamic 18F-fluoro-ethyl-tyrosine positron emission tomography/computed tomography: A better predictor of isocitrate dehydrogenase mutation in presurgical evaluations of glioma


1 Department of Nuclear Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India
2 Department of Histopathology, Post Graduate Institute of Medical Education and Research, Chandigarh, India
3 Department of Neurosurgery, Post Graduate Institute of Medical Education and Research, Chandigarh, India
4 Department of Radiodiagnosis and Imaging, Post Graduate Institute of Medical Education and Research, Chandigarh, India

Date of Submission18-Jun-2020
Date of Decision24-Jun-2020
Date of Acceptance02-Jul-2020
Date of Web Publication21-Oct-2020

Correspondence Address:
Dr. Ashwani Sood
Department of Nuclear Medicine, PGIMER, Sector-12, Chandigarh - 160 012
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijnm.IJNM_135_20

Rights and Permissions
   Abstract 


The recent WHO classification of gliomas has incorporated molecular markers such as isocitrate dehydrogenase (IDH) mutation and 1p/19q co-deletion into the ambit of morphological diagnosis, and 18F-fluoro-ethyl-tyrosine (18F-FET) positron emission tomography (PET) has shown its utility in noninvasive glioma grading and prognosis. Both dynamic and static FET PET parameters may assist in predicting the IDH mutational status, but time to peak derived from dynamic data may be a better predictor for IDH status. We present a case of left frontal lobe lesion suggestive of high-grade glioma on magnetic resonance imaging and static 18F-FET PET images, however, dynamic FET image was suggestive of low-grade IDH1-mutated glioma which was later confirmed on histology and immunohistochemistry.

Keywords: 18F-fluoro-ethyl-tyrosine, glioma, isocitrate dehydrogenase, positron emission tomography/computed tomography


How to cite this article:
Raj Tigapuram KN, Gupta K, Sood A, Singla N, Rana N, Vatsa R, Ahuja CK, Mittal BR. Dynamic 18F-fluoro-ethyl-tyrosine positron emission tomography/computed tomography: A better predictor of isocitrate dehydrogenase mutation in presurgical evaluations of glioma. Indian J Nucl Med 2020;35:367-9

How to cite this URL:
Raj Tigapuram KN, Gupta K, Sood A, Singla N, Rana N, Vatsa R, Ahuja CK, Mittal BR. Dynamic 18F-fluoro-ethyl-tyrosine positron emission tomography/computed tomography: A better predictor of isocitrate dehydrogenase mutation in presurgical evaluations of glioma. Indian J Nucl Med [serial online] 2020 [cited 2020 Nov 26];35:367-9. Available from: https://www.ijnm.in/text.asp?2020/35/4/367/298739



A 36-year-old man on anti-epileptic treatment for intermittent episodes of generalized tonic–clonic seizures, loss of consciousness, and headache was referred for further work-up. Magnetic resonance imaging (MRI) of brain done revealed a heterogeneous T1 hypointense, T2/fluid-attenuated inversion recovery heterogeneously hyperintense lesion in the left frontal lobe showing increase blood flow, areas of necrosis with significant mass effect-features suggestive of high-grade glioma [Figure 1]a. 18F-fluoro-ethyl-tyrosine (18 F-FET) positron emission tomography (PET)/computed tomography (CT) dynamic images were acquired immediately after injection in list mode for 40 min. Dynamic image data were reconstructed with 14 frames comprising 5 frames × 1 min, 5 frames × 3 min, and 4 frames × 5 min, and a static image was reconstructed by summing the images from 20 to 40 min postinjection. The time–activity curve (TAC) from dynamic image showed a delayed time to peak (TTP) and rising curve (Type II curve) suggestive of low-grade glioma with prediction for isocitrate dehydrogenase (IDH1)- mutated glioma [Figure 2], though static PET/CT images showed tracer-avid ill-defined enhancing subcentimetric lesion (SUVmax: 3.2) in the left prefrontal cortex [Figure 1]b and [Figure 1]c. Histology revealed a diffuse astrocytoma (WHO Grade II) characterized by moderately pleomorphic cells set against a pale fibrillary background. No mitoses, endovascular proliferation, or necrosis was identified. On molecular subtyping, the cells were mutant for IDH1 R132H protein with loss of expression for ATRX (ATRX-mutant phenotype). No positivity was noted for p53-mutant protein [Figure 3]a, [Figure 3]b, [Figure 3]c, [Figure 3]d.
Figure 1: Magnetic resonance imaging axial section of the brain revealing a heterogeneous T1 postcontrast heterogeneously enhancing lesion in the left frontal lobe (a). Static images of computed tomography and fused positron emission tomography/computed tomography showing tracer-avid ill-defined enhancing subcentimetric lesion (SUVmax: 3.2) in the left prefrontal cortex (b and c)

Click here to view
Figure 2: Time–activity curve from dynamic image showing a delayed time to peak and rising curve (Type II curve) suggestive of low-grade glioma with prediction for isocitrate dehydrogenase 1-mutated glioma

Click here to view
Figure 3: Histopathology revealing a diffuse astrocytoma (WHO grade II) characterized by moderately pleomorphic cells set against a pale fibrillary background. No mitoses, endovascular proliferation, or necrosis is identified (a, H&E x200; b, H&E x400). c: Neoplastic cells revealed immunoreactivity for IDH1 R132H mutant protein; d: Loss of expression for ATRX protein (mutant phenotype). (c,d: immunoperoxidase x400)

Click here to view


Presurgical evaluation of central nervous system tumors is critical for assessing the lesion for tumor type, grade, and extent. MRI is the primary imaging investigation in the evaluation of brain tumors.[1],[2] Recently, the WHO 2016 classification has incorporated IDH mutational status in the diagnosis of gliomas which has prognostic implications such that IDH-mutant tumors have a more favorable outcome compared to IDH wild type.[3],[4] The noninvasive techniques to predict the molecular characteristics of tumors are increasingly being explored, and dynamic and static FET PET images have shown promising results.[5],[6] For primary diagnosis, a cutoff threshold for SUVmax >1.6–1.8 using FET has been suggested to differentiate between high versus low-grade tumors. Increased tracer uptake is reported to have a high positive predictive value for high-grade lesions, though low-grade lesions, especially oligodendroglioma, may even show high uptake.[7]

Recently, new EANM/RANO guidelines for PET imaging in gliomas suggested that dynamic parameters from FET PET/CT with assessment of TTP by measuring the time of tumor peak uptake can help in distinguishing the grade of gliomas better than static images.[7] In a study, more patients with IDH wild-type gliomas showed FET positivity (TBRmax > 1.6) with higher median TBRmax than patients of IDH-mutant gliomas, but reliable cutoff could not be achieved because of high overlap. However, dynamic data showed significantly shorter TTP for IDH wild-type gliomas with high positive predictive value.[8] The shape and TTP in the TAC on dynamic images may be indicative of tumor grade. The continuous increasing uptake in TAC is frequently observed in Grade I/II gliomas, though this pattern may also be seen in radiation-induced changes, inflammatory lesions, hematoma, or infarction.[7] In the index case, MRI and high SUVmax on static FET imaging were indicative of high-grade glioma, while dynamic FET imaging suggestive of low-grade correlated with histopathological findings suggesting that dynamic data may be more useful in predicting the molecular characteristics.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
   References Top

1.
Upadhyay N, Waldman AD. Conventional MRI evaluation of gliomas. Br J Radiol 2011;84:S107-11.  Back to cited text no. 1
    
2.
Weller M, van den Bent M, Tonn JC, Stupp R, Preusser M, Cohen-Jonathan-Moyal E, et al. European association for neuro-oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol 2017;18:e315-29.  Back to cited text no. 2
    
3.
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: A summary. Acta Neuropathol 2016;131:803-20.  Back to cited text no. 3
    
4.
Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 2015;372:2499-508.  Back to cited text no. 4
    
5.
Verger A, Stoffels G, Bauer EK, Lohmann P, Blau T, Fink GR,et al. Static and dynamic (18)F-FET PET for the characterization of gliomas defined by IDH and 1p/19q status. Eur J Nucl Med Mol Imaging. 2018;45:443–51.  Back to cited text no. 5
    
6.
Lopci E, Riva M, Olivari L, Raneri F, Soffietti R, Piccardo A, et al. Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma. Eur J Nucl Med Mol Imaging. 2017;44:1155–64.  Back to cited text no. 6
    
7.
Law I, Albert NL, Arbizu J, Boellaard R, Drzezga A, Galldiks N, et al. Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18 F]FDG: version 1.0. Eur J Nucl Med Mol Imaging 2019;46:540-57.  Back to cited text no. 7
    
8.
Vettermann F, Suchorska B, Unterrainer M, Nelwan D, Forbrig R, Ruf V, et al. Non-invasive prediction of IDH-wildtype genotype in gliomas using dynamic 18F-FET PET. Eur J Nucl Med Mol Imaging 2019;46:2581-9.  Back to cited text no. 8
    


    Figures

  [Figure 1], [Figure 2], [Figure 3]



 

Top
  
 
  Search
 
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    Abstract
    References
    Article Figures

 Article Access Statistics
    Viewed62    
    Printed0    
    Emailed0    
    PDF Downloaded11    
    Comments [Add]    

Recommend this journal